Laurus Labs

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.

Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Stocks to buy: Ajit Mishra of Religare Broking recommends buying BSE and Laurus Labs; also suggests Nifty trading strategy

Motilal Oswal remains positive on Laurus due to its strengthening position in gaining CDMO contracts, the addition of a growth lever in the generics space, and a steady ARV business.

The management expects better Q4 and a decent overall growth in FY27

Stocks to buy today, February 26, 2026: Kunal Kamble of Bonanza Portfolio recommends buying Laurus Labs, Tata Steel, and Graphite India; here's why

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

The stock hit a new high of ₹1,095, appreciated 117% from its 52-week low of ₹504.30 touched on January 28, 2025.

Laurus Labs management said the fundamentals of the company's business remain strong, with sustained growth momentum in the Contract Development and Manufacturing Organization and Generic business.

BSE, Hitachi Energy, GE Vernova, Syrma SGS, Force Motors, HBL Engineering and Laurus Labs have gained more than 50% each after these companies reported over 50% growth in profit in Q1 and Q2 of FY26.

Among the companies trading ex-dividend on Friday, Coforge has declared an interim dividend of ₹4 per share, with the record date set for the same day

HDFC Bank (HDFCB) reported a steady Q2FY26, with profit rising 11 per cent Y-o-Y to ₹186.4 billion, aided by healthy NII of ₹315.5 billion and strong treasury gains of ₹23.9 billion

Thus far in the month of October 2025, Laurus Labs has outperformed the market by surging 14 per cent.

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Q2FY26 company results: Many firms including PTC India Financial Services, Tata Teleservices, Jumbo Bag and Vardhman Textiles are also to release their July-September quarter earnings reports today